الإحصائيات الأساسية
| CIK | 1724521 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Arcus Biosciences, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 6, 2025 |
Exhibit 99.1 Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update August 6, 2025 •PEAK-1, a Phase 3 study evaluating casdatifan + cabozantinib in immunotherapy (IO)-experienced ccRCC, and eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca evaluating casdatifan + volrustomig in first-line metastatic ccRCC, have been initiated •Data from ARC-20 evalua |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| June 12, 2025 |
Non-Employee Director Compensation Program Exhibit 10.1 ARCUS BIOSCIENCES, INC. AMENDED COMPENSATION PROGRAM FOR NON-EMPLOYEE DIRECTORS EFFECTIVE AS OF JUNE 10, 2025 A.Cash Compensation Annual cash retainers each paid quarterly, in arrears, as follows: 1 Retainer for each non-employee member of the Board: $50,000 2 Additional retainer for Lead Independent Director: $30,000 3 Additional retainer for Chair of Audit Committee: $20,000 4 Addit |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2025 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| May 6, 2025 |
Exhibit 99.1 Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update May 6, 2025 •Data from the Phase 1/1b ARC-20 study cohort evaluating casdatifan plus cabozantinib in immunotherapy (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meetin |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 22, 2025 |
Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. |
|
| April 22, 2025 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 25, 2025 |
Separation Agreement, between the Registrant and Dimitry Nuyten, dated January 16, 2025 EXHIBIT 10.42 January 16, 2025 Dimitry Nuyten, MD, Ph.D. [ADDRESS] Dear Dimitry: This letter sets forth the substance of the separation agreement (the “Agreement”) that Arcus Biosciences (the “Company”) is offering to you to aid in your employment transition. 1.Separation. Your last day of work with the Company and your employment termination date will be January 31, 2025 (the “Separation Date”). |
|
| February 25, 2025 |
Exhibit 99.1 Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update February 25, 2025 •New data from the Phase 1/1b ARC-20 study showed that casdatifan improved upon the rate of primary progression, overall response rate (ORR) and progression-free survival (PFS) relative to published data from studies with HIF-2a inhibitors to date •Initiation |
|
| February 25, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Arcus Biosciences, Inc. |
|
| February 25, 2025 |
Letter Agreement, dated January 13, 2025, between the Registrant and Richard Markus, MD., Ph.D. January 13, 2025 Richard Markus, M.D., Ph.D. [ADDRESS] Dear Richard: On behalf of Arcus Biosciences, Inc. (“Arcus” or the “Company”), I am pleased to invite you to join the Company in the role of Chief Medical Officer, reporting initially to Terry Rosen, CEO. Once you begin, Terry can provide you with additional information regarding your role and responsibilities. We believe this position creates |
|
| February 25, 2025 |
EXHIBIT 19.1 ARCUS BIOSCIENCES, INC. Insider Trading Policy Purpose. It is illegal for anyone to trade in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. It is also illegal to share material nonpublic information with others who may trade on the basis of such information. Companies who fail to take reasonable steps t |
|
| February 25, 2025 |
As filed with the Securities and Exchange Commission on February 25, 2025 As filed with the Securities and Exchange Commission on February 25, 2025 Registration No. |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-384 |
|
| February 20, 2025 |
EX-99.1 3 lockupagreement.htm LOCK-UP AGREEMENT Exhibit 99.1 Arcus Biosciences, Inc. Lock-Up Agreement February 17, 2025 Goldman Sachs & Co. LLC Leerink Partners LLC As Representatives of the several Underwriters named in Schedule I to the Underwriting Agreement c/o Goldman Sachs & Co. LLC 200 West Street New York, NY 10282-2198 c/o Leerink Partners LLC 53 State St Boston, MA 02110 Re: Arcus Biosc |
|
| February 19, 2025 |
Exhibit 1.1 EXECUTION VERSION Arcus Biosciences, Inc. Common Stock ($0.0001 par value) Underwriting Agreement February 18, 2025 Goldman Sachs & Co. LLC Leerink Partners LLC As Representatives of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, NY 10282-2198 c/o Leerink Partners LLC 53 State St Boston, MA 02109 To the addressees set forth abo |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2025 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 18, 2025 |
13,636,364 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-270132 PROSPECTUS SUPPLEMENT (To Prospectus dated February 28, 2023) 13,636,364 Shares Common Stock We are offering 13,636,364 shares of our common stock. Our common stock is listed on the New York Stock Exchange under the symbol “RCUS.” On February 14, 2025, the last reported sale price of our common stock was $13.10 per shar |
|
| February 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Arcus Biosciences, Inc. |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 06, 2025 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 17, 2024 |
RCUS / Arcus Biosciences, Inc. / ROSEN TERRY J - SC 13D/A Activist Investment SC 13D/A United States Securities And Exchange Commission Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Arcus Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03969F109 (CUSIP Number) Terry Rosen, Ph.D. Arcus Biosciences, Inc. 3928 Point Eden Way Hayward, CA 94545 Telephone: (510) 694-6200 (Name, Add |
|
| November 6, 2024 |
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update Exhibit 99.1 Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update •Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (19%) and promising objective response rate (34% with 2 responses pending confirmation, 25% confirmed) for the 100mg daily (50 |
|
| November 6, 2024 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of August 27, 2024 and is entered into by and among ARCUS BIOSCIENCES, INC., a Delaware corporation (“Company”), each of its Subsidiaries from time to time party hereto as borrower (individually or collectively with the Company, as the context may require, “Borrower”), and the several banks and other fin |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 17, 2024 |
RCUS / Arcus Biosciences, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 ArcusBiosciencesInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ARCUS BIOSCIENCES INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03969F109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pur |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2024 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 8, 2024 |
Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update Exhibit 99.1 Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update •Data from the casdatifan 100 mg expansion cohort of ARC-20, a Phase 1/1b study in clear cell renal cell carcinoma (ccRCC), are expected to be presented at a medical conference in the fourth quarter of 2024 •PEAK-1, the initial Phase 3 study evaluating casdatifan in combination with cabozant |
|
| August 8, 2024 |
Exhibit 10.1 AMENDMENT NO. 4 TO OPTION, LICENSE AND COLLABORATION AGREEMENT This Amendment No. 4 (“Amendment No. 4”) to the Option, License and Collaboration Agreement, dated as of May 2, 2020, as amended November 17, 2021, May 12, 2023 and January 29, 2024 (collectively, the “Agreement”), is entered into as of May 10, 2024 (the “Amendment No. 4 Execution Date”), by and between Gilead Sciences, In |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 6, 2024 |
Non-Employee Director Compensation Program Exhibit 10.1 ARCUS BIOSCIENCES, INC. AMENDED COMPENSATION PROGRAM FOR NON-EMPLOYEE DIRECTORS EFFECTIVE AS OF JUNE 6, 2024 A.Cash Compensation Annual cash retainers each paid quarterly, in arrears, as follows: Retainer for each non-employee member of the Board: $45,000 Additional retainer for Lead Independent Director: $25,000 Additional retainer for Chair of Audit Committee: $20,000 Additional ret |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2024 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 23, 2024 |
EZFB: E + Z + mFOLFOX-6 ± beva Exhibit 99.1 ARC-9: A Randomized Study to Evaluate Etrumadenant Based Treatment Combinations in Previously Treated Metastatic Colorectal Cancer (mCRC) Authors: Zev A. Wainberg1, Sae-Won Han2, Soohyeon Lee3, Keun-Wook Lee4, Scott Kopetz5, Jonathan Mizrahi6, Yong Sang Hong7, Francois Ghiringhelli8, Antoine Italiano9, David Tougeron10, Brandon Beagle11, Mathew Boakye11, Tingting Zhao11, Joon Rhee12, |
|
| May 23, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 8, 2024 |
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update Exhibit 99.1 Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update •Arcus data will be disclosed in two oral presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting ◦Updated data, including median progression-free survival (PFS), from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper GI cancers ◦Da |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| April 23, 2024 | ||
| April 23, 2024 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 21, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Arcus Biosciences, Inc. |
|
| February 21, 2024 |
Arcus Biosciences, Inc. Severance Benefits Plan. Exhibit 10.4 ARCUS BIOSCIENCES, INC. SEVERANCE BENEFITS PLAN EFFECTIVE AS OF FEBRUARY 20, 2024 1.Establishment and Purpose of Plan. This Arcus Biosciences, Inc. Severance Benefits Plan (the “Plan”) has been established by Arcus Biosciences, Inc. as of the effective date set forth above. The purpose of the Plan is to provide eligible employees of the Company with severance benefits in the event of |
|
| February 21, 2024 |
Exhibit 97.1 ARCUS BIOSCIENCES, INC. Compensation Clawback Policy Purpose and Scope; Administration. The board of directors (the “Board”) of Arcus Biosciences, Inc. (the “Company”) has adopted this compensation clawback policy (the “Policy”) to provide for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial |
|
| February 21, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 21, 2024 |
Exhibit 99.1 Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update •Arcus and Gilead announced an additional equity investment of $320 million into Arcus and modifications to their domvanalimab + zimberelimab clinical program to focus on the highest unmet medical needs and largest market opportunities •Pharmacokinetic (PK), pharmacodynamic (PD |
|
| February 21, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Arcus Biosciences, Inc. |
|
| February 21, 2024 |
As filed with the Securities and Exchange Commission on February 21, 2024 As filed with the Securities and Exchange Commission on February 21, 2024 Registration No. |
|
| February 21, 2024 |
Exhibit 10.35 [***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED Confidential Execution Version AMENDMENT NO. 3 TO OPTION, LICENSE AND COLLABORATION AGREEMENT This Amendment No. 3 (this “Amendment No. 3”) to the Option, License and Collaboration Agreement, dated as of May 27, 2020, as amended as of November 17, 2021 |
|
| February 21, 2024 |
As filed with the Securities and Exchange Commission on February 21, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 21, 2024 Registration No. |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-384 |
|
| February 13, 2024 |
RCUS / Arcus Biosciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0324-arcusbiosciencesinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Arcus Biosciences Inc Title of Class of Securities: Common Stock CUSIP Number: 03969F109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to des |
|
| January 31, 2024 |
Exhibit 99.1 [***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS OF THE TYPE THAT THE REPORTING PERSON CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL ARCUS BIOSCIENCES, INC. THIRD AMENDED AND RESTATED COMMON STOCK PURCHASE AGREEMENT This Third Amended and Restated Common Stock Purchase Agreement (this “Agreement”) is dated as of January 29, 202 |
|
| January 31, 2024 |
Exhibit 99.2 [***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ARCUS BIOSCIENCES, INC. AMENDED & RESTATED INVESTOR RIGHTS AGREEMENT This Amended and Restated Investor Rights Agreement (this “Agreement”) is made as of January 29, 2024 (the “Effective Date”), by and between Arcus Biosciences, Inc., a Delaware corpora |
|
| January 31, 2024 |
RCUS / Arcus Biosciences, Inc. / GILEAD SCIENCES INC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* ARCUS BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03969F109 (CUSIP Number) Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 650-574-3000 (Name, Address and Telephone Number of Pe |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 30, 2024 |
Exhibit 99.1 Gilead Contacts: Jacquie Ross, Investors [email protected] Meaghan Smith, Media [email protected] Arcus Contacts: Pia Eaves, Investors [email protected], (617) 459-2006 Holli Kolkey, Media [email protected], (650) 922-1269 GILEAD AND ARCUS ANNOUNCE AMENDED COLLABORATION AND EQUITY INVESTMENT – Investment Reinforces Companies’ Conviction in TIGIT Pathway and Prov |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 7, 2023 |
Memorandum, dated July 27, 2023, between Arcus Biosciences, Inc. and Taiho Pharmaceutical Co., LTD. Exhibit 10.1 [***] = INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT ARCUS BIOSCIENCES, INC. TREATS AS PRIVATE OR CONFIDENTIAL MEMORANDUM This memorandum (this “Memorandum”) is made and entered into effective as of July 27, 2023 (the “Effective Date”) by and between Arcus Biosciences, Inc., a company organized under the laws of State of Delaware, U. |
|
| November 7, 2023 |
Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update Exhibit 99.1 Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update •Data were presented from the ongoing EDGE-Gastric Phase 2 study in first-line upper GI cancers at the Annual Meeting of the American Society of Clinical Oncology (ASCO) Plenary Series; domvanalimab is the only Fc-silent anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas and has the |
|
| August 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2023 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 7, 2023 |
Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update Exhibit 99.1 Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update • Presented data from the ongoing ARC-7 Phase 2 trial in non-small cell lung cancer at American Society of Clinical Oncology (ASCO); Fc-silent anti-TIGIT monoclonal antibody domvanalimab continued to demonstrate clinically meaningful improvements over anti-PD-1 monotherapy across all measure |
|
| August 7, 2023 |
Exhibit 10.1 [***] CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT NO. 2 TO OPTION, LICENSE AND COLLABORATION AGREEMENT This Amendment No. 2 (this “Amendment No. 2”) to the Option, License and Collaboration Agreement, dated as of May 27, 2020, as amended as of November 17, 2021 (collectively, the “Agreement”), |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| July 6, 2023 |
RCUS / Arcus Biosciences Inc / GILEAD SCIENCES INC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ARCUS BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03969F109 (CUSIP Number) Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 650-574-3000 (Name, Address and Telephone Number of Pe |
|
| July 6, 2023 |
Exhibit 99.1 [***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS OF THE TYPE THAT THE REPORTING PERSON CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL ARCUS BIOSCIENCES, INC. SECOND AMENDED AND RESTATED COMMON STOCK PURCHASE AGREEMENT This Second Amended and Restated Common Stock Purchase Agreement (this “Agreement”) is dated as of June 27, 2023, by and b |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 16, 2023 |
Compensation Program for Non-Employee Directors EXHIBIT 10.1 ARCUS BIOSCIENCES, INC. AMENDED COMPENSATION PROGRAM FOR NON-EMPLOYEE DIRECTORS EFFECTIVE AS OF JUNE 15, 2023 A. Cash Compensation Annual cash retainers each paid quarterly, in arrears, as follows: 1. Retainer for each non-employee member of the Board: $45,000 2. Additional retainer for Lead Independent Director: $25,000 3. Additional retainer for Chair of Audit Committee: $20,000 4. |
|
| June 16, 2023 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 03, 2023 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 15, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| May 9, 2023 |
Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update Exhibit 99.1 Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update • Four Phase 3 and two Phase 2 trials are now enrolling to evaluate domvanalimab-based combinations in lung and gastrointestinal cancers. • The third dose-escalation cohort (100mg) of ARC-20 for AB521, a potential best-in-class HIF-2a inhibitor, is enrolling; the dose-expansion stage of ARC-2 |
|
| April 21, 2023 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 21, 2023 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 09, 2023 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 28, 2023 |
Exhibit 99.1 Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update • At the American Society of Clinical Oncology (ASCO) Plenary session in December 2022, interim data were presented from the ARC-7 study, which demonstrated a median PFS of ~12.0 months for domvanalimab plus zimberelimab vs 5.4 months for zimberelimab alone. • In 2022, Arcus an |
|
| February 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Arcus Biosciences, Inc. |
|
| February 28, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| February 28, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| February 28, 2023 |
List of subsidiaries of the registrant. Exhibit 21.1 List of Subsidiaries Name of Subsidiary State or Jurisdiction in Which Incorporated or Organized Arcus Biosciences Australia PTY LTD Australia |
|
| February 28, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Arcus Biosciences, Inc. |
|
| February 28, 2023 |
EXHIBIT 10.28 EXECUTION COPY [***] = INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT ARCUS BIOSCIENCES, INC. TREATS AS PRIVATE OR CONFIDENTIAL AMENDMENT NO. 4 TO LICENSE AGREEMENT This AMENDMENT NO. 4 (the “Amendment”) is made and entered into as of December 30, 2022 (“Effective Date”), by and between Arcus Biosciences, Inc. (“Arcus”), with offices |
|
| February 28, 2023 |
Form of Common Stock Warrant Agreement and Certificate EX-4.8 Exhibit 4.8 ARCUS BIOSCIENCES, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF ARCUS BIOSCIENCES, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ARCUS BIOSCIENCES, INC. a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and exist |
|
| February 28, 2023 |
EX-1.2 2 d426898dex12.htm EX-1.2 Exhibit 1.2 ARCUS BIOSCIENCES, INC. Common Stock ($0.0001 par value) Having an Aggregate Offering Price of up to $200,000,000 Equity Distribution Agreement February 28, 2023 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 SVB Securities LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Arcus Biosciences, Inc |
|
| February 28, 2023 |
Form of Preferred Stock Warrant Agreement and Certificate EX-4.9 Exhibit 4.9 ARCUS BIOSCIENCES, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF ARCUS BIOSCIENCES, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ARCUS BIOSCIENCES, INC. a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38419 Arcus Bioscienc |
|
| February 14, 2023 |
RCUS / Arcus Biosciences Inc / PFM Health Sciences, LP - SC 13G/A Passive Investment |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Arcus Biosciences, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 03969F109 (CUSIP Number) |
|
| February 10, 2023 |
RCUS / Arcus Biosciences Inc / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 rcus13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Arcus Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03969F109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 9, 2023 |
RCUS / Arcus Biosciences Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Arcus Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 03969F109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 2, 2022 |
Letter Agreement, dated July 25, 2022, between the Registrant and Dimitry S.A. Nuyten, MD., Ph.D. Exhibit 10.3 July 25, 2022 Dear Dimitry: On behalf of Arcus Biosciences, Inc. (?Arcus? or the ?Company?), I am pleased to invite you to join the Company in the role of Chief Medical Officer. Below are details of the compensation and benefits program that we offer, as well as other terms of your employment with Arcus. Should you have any questions regarding any part of this offer, or wish to receiv |
|
| November 2, 2022 |
Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update Exhibit 99.1 Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update • Arcus and Gilead Sciences are pursuing a broad development strategy for their anti-TIGIT antibody domvanalimab in lung cancer, which now includes three ongoing registrational Phase 3 trials in multiple non-small cell lung cancer (NSCLC) settings; as part of this strategy, the companies have |
|
| November 2, 2022 |
we UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| November 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2022 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 17, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Arcus Biosciences, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the u |
|
| October 17, 2022 |
RCUS / Arcus Biosciences Inc / PFM Health Sciences, LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Arcus Biosciences, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 03969F109 (CUSIP Number) October 6, 2022 (Date of Event Which Requires |
|
| October 11, 2022 |
Amendment No. 1 to Investor Rights Agreement, dated October 11, 2022 Exhibit 10.1 AMENDMENT NO. 1 TO INVESTOR RIGHTS AGREEMENT This Amendment No. 1 (the ?Amendment?) to the Investor Rights Agreement dated May 27, 2020 (?Agreement?), is entered into as of October 11, 2022 (the ?Amendment Execution Date?), by and between Arcus Biosciences, Inc. (?Arcus?) and Gilead Sciences, Inc. (?Gilead?). Capitalized terms used and not otherwise defined herein shall have the meani |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2022 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 11, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Arcus Biosciences, Inc. |
|
| October 11, 2022 |
As filed with the Securities and Exchange Commission on October 11, 2022 S-3ASR 1 d378586ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on October 11, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Arcus Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3893435 (State or other j |
|
| August 3, 2022 |
Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update Exhibit 99.1 Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update ? Four registrational Phase 3 trials evaluating domvanalimab-based combinations are ongoing or expected to start by year-end; Arcus and Gilead Sciences continue to expand their late-stage clinical program for domvanalimab with the goal of establishing a best-in-class anti-TIGIT antibody regi |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| August 3, 2022 |
Letter Agreement with Gilead Sciences, Inc., dated July 1, 2022. Exhibit 10.2 [***] = INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT ARCUS BIOSCIENCES, INC. TREATS AS PRIVATE OR CONFIDENTIAL July 1, 2022 Arcus Biosciences, Inc. 3928 Point Eden Way Hayward, CA 94545 Attention: General Counsel Re: Collaboration on Gilead?s CD73 program Dear Ladies and Gentlemen: The letter agreement (?Letter Agreement?) makes refe |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2022 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 16, 2022 |
Non-Employee Director Compensation Program EXHIBIT 10.1 ARCUS BIOSCIENCES, INC. AMENDED COMPENSATION PROGRAM FOR NON-EMPLOYEE DIRECTORS EFFECTIVE AS OF JUNE 14, 2022 A. Cash Compensation: Annual cash retainers each paid quarterly, in arrears. 1. Retainer for each non-employee member of the Board: $45,000 2. Additional retainer for Lead Independent Director: $5,000 3. Additional retainer for Chair of Audit Committee: $20,000 4. Additional r |
|
| June 16, 2022 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 3, 2022 |
Arcus Biosciences, Inc. 3928 Point Eden Way Hayward, California 94545 Arcus Biosciences, Inc. 3928 Point Eden Way Hayward, California 94545 VIA EDGAR June 3, 2022 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Al Pavot and Terence O'Brien Re: Arcus Biosciences, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 10-K filed February 23, 2022 File No. 1-38419 Ladies and Gentlemen: |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2022 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 9, 2022 |
Exhibit 99.1 Arcus Biosciences Reports First Quarter 2022 Financial Results and Provides a Pipeline Update, Including from the Third Interim Analysis for the ARC-7 Study ? In a third interim analysis for the randomized Phase 2 ARC-7 study, both anti-TIGIT domvanalimab-containing arms continued to show meaningful differentiation compared to the anti-PD1 antibody zimberelimab alone when given as a t |
|
| April 20, 2022 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 20, 2022 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 14, 2022 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated March 14, 2022 with respect to the Common Stock, par value $0.0001 per share, of Arcus Biosciences, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance wit |
|
| March 14, 2022 |
RCUS / Arcus Biosciences Inc / BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Arcus Biosciences, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 03969F109 (CUSIP Number) |
|
| February 23, 2022 |
Arcus Biosciences, Inc. Amended and Restated 2020 Inducement Plan EXHIBIT 10.18 Arcus Biosciences, Inc. 2020 Inducement Plan Adopted by the Board of Directors: January 22, 2020 Amended: November 24, 2020 Amended: February 18, 2021 Amended: December 27, 2021 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Rule 303A.08 of the NYSE |
|
| February 23, 2022 |
List of subsidiaries of the registrant Exhibit 21.1 List of Subsidiaries Name of Subsidiary State or Jurisdiction in Which Incorporated or Organized Arcus Biosciences Australia PTY LTD Australia |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38419 Arcus Bioscienc |
|
| February 23, 2022 |
EXHIBIT 10.34 [***] = INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT ARCUS BIOSCIENCES, INC. TREATS AS PRIVATE OR CONFIDENTIAL AMENDMENT NO. 1 TO OPTION, LICENSE AND COLLABORATION AGREEMENT This Amendment No. 1 (this ?Amendment?) to the Option, License and Collaboration Agreement, dated as of May 27, 2020 (the ?Agreement?), is entered into as of No |
|
| February 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 23, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Arcus Biosciences, Inc. |
|
| February 23, 2022 |
Exhibit 99.1 Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update ? Presentations of randomized data for domvanalimab and etrumadenant in 1L PD-L1 high non-small cell lung cancer (NSCLC; ARC-7) and quemliclustat in pancreatic cancer (ARC-8) are planned for 2H:22 ? Initial pharmacokinetic (PK)/pharmacodynamic(PD) data for AB521, Arcus?s HIF-2a |
|
| February 23, 2022 |
As filed with the Securities and Exchange Commission on February 23, 2021 As filed with the Securities and Exchange Commission on February 23, 2021 Registration No. |
|
| February 14, 2022 |
RCUS / Arcus Biosciences Inc / PFM Health Sciences, LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Arcus Biosciences, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 03969F109 (CUSIP Number) December 31, 2021 Date of Event Which Requi |
|
| February 14, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G/A filed herewith (and any amendments thereto), relating to the common stock of Arcus Biosciences, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the |
|
| February 14, 2022 |
RCUS / Arcus Biosciences Inc / GV 2016, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Arcus Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03969F109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 14, 2022 |
RCUS / Arcus Biosciences Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Arcus Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03969F109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2022 |
EXHIBIT A Agreement of Joint Filing The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of Arcus Biosciences, Inc. |
|
| December 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2021 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 18, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2021 Arcus Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38419 47-3898435 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| November 8, 2021 |
Exhibit 99.1 Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab ? Both domvanalimab-containing arms demonstrated differentiated clinical activity compared to that of zimberelimab alone in a second interim analysis of ARC-7, our randomized Phase 2 study in first-line metastatic non-small cell lung cancer (NSCLC) ? Gilead Sciences has |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 ARCUS BIOSCIENCES, INC. |
|
| August 5, 2021 |
EXHIBIT 10.2 [***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 3 TO LICENSE AGREEMENT This AMENDMENT NO. 3 (the ?Amendment?) is made and entered into as of May 10, 2021 (?Effective Date?), by and between Arcus Biosciences, Inc. (?Arcus?), with offices at 3928 Point Eden Wa |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| August 5, 2021 |
Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights Exhibit 99.1 Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights ? All five clinical-stage molecules continue to advance with six ongoing randomized Phase 2 and Phase 3 studies in major tumor types, including lung, colon, prostate and pancreatic cancer ? AB521, a small molecule HIF-2? inhibitor, expected to enter the clinic in 4Q21 ? Reported encoura |
|
| August 5, 2021 |
EXHIBIT 10.3 July 16, 2021 Dear Bill: This letter confirms the terms and conditions of your voluntary resignation of employment with Arcus Biosciences, Inc. (the ?Company?), as well as the benefits the Company will provide to you in exchange for your consent to be bound by the terms of this letter agreement (?Agreement?). 1.Separation. Your last day of work with the Company and your employment ter |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 ARCUS BIOSCIENCES, INC. |
|
| July 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2021 ARCUS BIOSCIENCES, INC. |
|
| July 19, 2021 |
RCUS / Arcus Biosciences Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Arcus Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 03969F109 (CUSIP Number) July 9, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| July 19, 2021 |
ARCUS CHIEF MEDICAL OFFICER TRANSITIONS TO ROLE AT GILEAD SCIENCES Exhibit 99.1 ARCUS CHIEF MEDICAL OFFICER TRANSITIONS TO ROLE AT GILEAD SCIENCES - Kartik Krishnan, M.D., Ph.D. and senior vice president will lead clinical development at Arcus HAYWARD, Calif. ? July 19, 2021 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bill Grossman M.D., Ph.D., will tra |
|
| June 7, 2021 |
Non-Employee Director Compensation Program EXHIBIT 10.1 ARCUS BIOSCIENCES, INC. AMENDED COMPENSATION PROGRAM FOR NON-EMPLOYEE DIRECTORS EFFECTIVE AS OF JUNE 3, 2021 A. Cash Compensation: Annual cash retainers each paid quarterly, in arrears. 1. Retainer for each non-employee member of the Board: $40,000 2. Additional retainer for Lead Independent Director: $5,000 3. Additional retainer for Chair of Audit Committee: $20,000 4. Additional re |
|
| June 7, 2021 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 ARCUS BIOSCIENCES, INC. |
|
| May 5, 2021 |
Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights Exhibit 99.1 Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights ? Continued to advance our portfolio of anti-TIGIT antibodies: On track for the ARC-7 interim analysis for domvanalimab in 2Q21, and the first patient was dosed with AB308 in combination with zimberelimab ? Presented promising PFS and OS data for etrumadenant in the ?3L metastatic colore |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 ARCUS BIOSCIENCES, INC. |
|
| May 5, 2021 |
Exhibit 10.2 FIFTH AMENDMENT TO LEASE This FIFTH AMENDMENT TO OFFICE LEASE ("Fifth Amendment") is made and entered into as of the 1st day of April, 2021 (the "Effective Date"), by and between HAYWARD POINT EDEN I LIMITED PARTNERSHIP, a Delaware limited partnership ("Landlord"), and ARCUS BIOSCIENCES, INC., a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant entered into tha |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2021 ARCUS BIOSCIENCES, INC. |
|
| April 20, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 20, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2021 ARCUS BIOSCIENCES, INC. |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2021 ARCUS BIOSCIENCES, INC. |
|
| February 25, 2021 |
Exhibit 10.36 Arcus Biosciences, Inc. 2018 Equity Incentive Plan Notice of Stock Option Grant You have been granted the following option to purchase shares of the common stock of Arcus Biosciences, Inc. (the ?Company?): Name of Optionee:?Name? Total Number of Shares:?TotalShares? Type of Option: ?ISO?Incentive Stock Option (ISO) ?NSO?Nonstatutory Stock Option (NSO) Exercise Price per Share:?PriceP |
|
| February 25, 2021 |
Arcus Biosciences, Inc. Amended and Restated 2020 Inducement Plan Exhibit 10.22 Arcus Biosciences, Inc. 2020 Inducement Plan Adopted by the Board of Directors: January 22, 2020 Amended: November 24, 2020 Amended: February 18, 2021 1.General. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Rule 303A.08 of the NYSE Listed Company Manual Rules. |
|
| February 25, 2021 |
As filed with the Securities and Exchange Commission on February 24, 2021 Registration No. |
|
| February 25, 2021 |
Exhibit 10.35 Dated November 10, 2020 Arcus Biosciences, Inc. WuXi Biologics (Cayman) Inc. and WuXi Biologics Ireland Limited ASSIGNMENT AGREEMENT THIS ASSIGNMENT AGREEMENT (?Agreement?) is made on November 10, 2020 (the ?Assignment Date?) by and among: (1) WuXi Biologics (Cayman) Inc., with an address at Ugland House, Grand Cayman, KY1-1104 Cayman Islands (the ?Licensor?); and (2) WuXi Biologics |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38419 Arcus Bioscienc |
|
| February 25, 2021 |
List of subsidiaries of the registrant. Exhibit 21.1 List of Subsidiaries Name of Subsidiary State or Jurisdiction in Which Incorporated or Organized Arcus Biosciences Australia PTY LTD Australia |
|
| February 25, 2021 |
Form of RSU Notice and Agreement under 2018 Equity Incentive Plan (for use from January 1, 2021) Exhibit 10.37 Arcus Biosciences, Inc. 2018 Equity Incentive Plan Notice of Restricted Stock Unit Award You have been granted Restricted Stock Units (?RSUs?), each representing the right to receive one share of common stock of Arcus Biosciences, Inc. (the ?Company?) on the following terms: Name of Recipient: ?Name? Total Number of RSUs Granted: ?TotalRSUs? Date of Grant: ?DateGrant? Vesting Schedul |
|
| February 25, 2021 |
Exhibit 4.3 ARCUS BIOSCIENCES, INC. DESCRIPTION OF COMMON STOCK Our authorized capital stock consists of 400,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share. A description of material terms and provisions of our certificate of incorporation and bylaws affecting the rights of holders of our common stock is set forth |
|
| February 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 ARCUS BIOSCIENCES, INC. |
|
| February 24, 2021 |
Exhibit 99.1 Arcus Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Highlights - Multiple key data read-outs expected for 2021, including the ARC-7 interim analysis in 2Q21 - Domvanalimab?s advancement into a registrational study coupled with recent IND clearance for AB308, Arcus?s FcR-enabled anti-TIGIT antibody, reinforces Arcus?s position as a lea |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Arcus Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03969F109 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 16, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G/A filed herewith (and any amendments thereto), relating to the common stock of Arcus Biosciences, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Arcus Biosciences, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 03969F109 (CUSIP Number) December 31, 2020 Date of Event Which Requi |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ARCUS BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03969F109 (CUSIP Number) Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 650-574-3000 (Name, Address and Telephone Number of Pe |
|
| February 2, 2021 |
Exhibit 99.1 [***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY SENSITIVE IF PUBLICLY DISCLOSED ARCUS BIOSCIENCES, INC. AMENDED AND RESTATED COMMON STOCK PURCHASE AGREEMENT This Amended and Restated Common Stock Purchase Agreement (this “Agreement”) is dated as of January 31, 2021, by and between Arcus Biosciences, Inc., a Delaware corporation ( |
|
| February 1, 2021 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2021 ARCUS BIOSCIENCES, INC. |
|
| January 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 ARCUS BIOSCIENCES, INC. |
|
| December 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2020 ARCUS BIOSCIENCES, INC. |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Arcus Biosciences, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 03969F109 (CUSIP Number) |
|
| November 9, 2020 |
RCUS / Arcus Biosciences, Inc. / PFM Health Sciences, LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Arcus Biosciences, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 03969F109 (CUSIP Number) October 29, 2020 Date of Event Which Requires |
|
| November 9, 2020 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Arcus Biosciences, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the u |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 ARCUS BIOSCIENCES, INC. |
|
| November 5, 2020 |
Offer letter by and between Arcus Biosciences, Inc. and Robert C. Goeltz II dated June 30, 2020 EXHIBIT 10.1 June 30, 2020 Bob Goeltz [Address] Dear Bob: On behalf of Arcus Biosciences, Inc. (“Arcus” or the “Company”), I am pleased to invite you to join the Company in the role of Chief Financial Officer. Below are details of the compensation and benefits program that we offer, as well as other terms of your employment with Arcus. Should you have any questions regarding any part of this offer |
|
| November 5, 2020 |
Offer letter by and between Arcus Biosciences, Inc. and Jennifer Jarrett dated September 10, 2020 EXHIBIT 10.2 September 10, 2020 Jennifer Jarrett [Address] Dear Jennifer: On behalf of Arcus Biosciences, Inc. (“Arcus” or the “Company”), I am pleased to invite you to join the Company in the role of Chief Operating Officer. Below are details of the compensation and benefits program that we offer, as well as other terms of your employment with Arcus. Should you have any questions regarding any pa |
|
| November 5, 2020 |
EXHIBIT 10.3 FOURTH AMENDMENT TO LEASE This FOURTH AMENDMENT TO LEASE ("Fourth Amendment") is made and entered into as of October 16, 2020, by and between HAYWARD POINT EDEN I LIMITED PARTNERSHIP, a Delaware limited partnership ("Landlord"), and ARCUS BIOSCIENCES, INC., a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant entered into that certain Lease dated September 30, 2 |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| November 5, 2020 |
Arcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates Exhibit 99.1 Arcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates - Commenced 10-year highly strategic partnership with Gilead to deliver next-generation cancer therapies - Recently announced collaboration with AstraZeneca for registrational trial, PACIFIC-8, further validates domvanalimab’s therapeutic potential - Significant readouts from multiple studies expect |
|
| November 4, 2020 |
RCUS / Arcus Biosciences, Inc. / COLUMN GROUP II, LP - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 4, 2020 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT We, the undersigned, hereby express our agreement that the attached Amendment No. 1 to Schedule 13G is filed on behalf of each of us. Dated: November 3, 2020 THE COLUMN GROUP II, LP THE COLUMN GROUP II GP, LP By: The Column Group II GP, LP By: /s/ Peter Svennilson By: /s/ Peter Svennilson Name: Peter Svennilson Name: Peter Svennilson Title: Managing Part |
|
| October 15, 2020 |
RCUS / Arcus Biosciences, Inc. / Jaen Juan C. - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Arcus Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969F109 (CUSIP Number) Juan Jaen, Ph.D. Arcus Biosciences, Inc. 3928 Point Eden Way Hayward, CA 94545 Telephone: (510) 694-6200 (Name, Address and Telephone Number of Person Authori |
|
| October 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2020 ARCUS BIOSCIENCES, INC. |
|
| August 6, 2020 |
Exhibit 10.4 THIRD AMENDMENT TO LEASE This THIRD AMENDMENT TO OFFICE LEASE ("Third Amendment") is made and entered into as of the 26th day of June, 2020 (the "Effective Date"), by and between HAYWARD POINT EDEN I LIMITED PARTNERSHIP, a Delaware limited partnership ("Landlord"), and ARCUS BIOSCIENCES, INC., a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant entered into tha |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 ARCUS BIOSCIENCES, INC. |
|
| August 6, 2020 |
Arcus Biosciences Announces Second Quarter 2020 Financial Results and Corporate Updates Exhibit 99.1 Arcus Biosciences Announces Second Quarter 2020 Financial Results and Corporate Updates ‒ Established a 10-year global partnership with Gilead to co-develop and co-commercialize next-generation cancer immunotherapies ‒ Strengthened balance sheet by raising approximately $348 million in gross proceeds from a public offering of Arcus’s common stock ‒ Presented early clinical activity of |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| August 6, 2020 |
EXHIBIT 10.1 [***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED OPTION, LICENSE AND COLLABORATION AGREEMENT by and between Arcus Biosciences, Inc. and Gilead Sciences, Inc. dated as of May 27, 2020 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 ARTICLE II GOVERNANCE 33 ARTICLE III ARCUS R&D ACTIVITIES AND OTHER TERM |
|
| July 17, 2020 |
RCUS / Arcus Biosciences, Inc. / GILEAD SCIENCES INC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ARCUS BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03969F109 (CUSIP Number) Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 650-574-3000 (Name, Address and Telephone Number of Per |
|
| July 13, 2020 |
EXHIBIT 99.1 [***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ARCUS BIOSCIENCES, INC. COMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (this “Agreement”) is dated as of May 27, 2020, by and between Arcus Biosciences, Inc., a Delaware corporation (the “Company”), and Gilead Sciences, Inc., a Del |
|
| July 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2020 ARCUS BIOSCIENCES, INC. |
|
| July 13, 2020 |
EXHIBIT 99.2 [***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED ARCUS BIOSCIENCES, INC. InVESTor RIGHTS AGREEMENT This Investor Rights Agreement (this “Agreement”) is made as of May 27, 2020 (the “Effective Date”), by and between Arcus Biosciences, Inc., a Delaware corporation (the “Company”) and Gilead Sciences, In |
|
| July 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2020 ARCUS BIOSCIENCES, INC. |
|
| June 5, 2020 |
Non-Employee Director Compensation Program EX-10.1 2 rcus-ex1016.htm EX-10.1 EXHIBIT 10.1 ARCUS BIOSCIENCES, INC. AMENDED COMPENSATION PROGRAM FOR NON-EMPLOYEE DIRECTORS EFFECTIVE AS OF JUNE 4, 2020 A. Cash Compensation: Annual cash retainers each paid quarterly, in arrears. 1. Retainer for each non-employee member of the Board: $40,000 2. Additional retainer for Lead Independent Director: $5,000 3. Additional retainer for Chair of Audit C |
|
| June 5, 2020 |
8-K 1 rcus-8k20200604.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2020 ARCUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38419 47-3898435 (State or other jurisdiction of i |
|
| May 29, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2019 ARCUS BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38419 47-3898435 (State or other jurisdiction of incorporation or organiza |
|
| May 29, 2020 |
EX-1.1 Exhibit 1.1 Arcus Biosciences, Inc. 11,000,000 Shares Common Stock ($0.0001 par value per share) Underwriting Agreement New York, New York May 28, 2020 Citigroup Global Markets Inc. SVB Leerink LLC Evercore Group L.L.C. As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o SVB Leerink LLC One Federal Street, 37th |
|
| May 29, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-238730 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, par value $0.0001 per share 12,650,000(2) $27.50 $347,875,000 $45,154.18 1) Calcu |
|
| May 28, 2020 |
SUBJECT TO COMPLETION, DATED MAY 27, 2020 424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| May 27, 2020 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 27, 2020 Registration No. |
|
| May 27, 2020 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2020 ARCUS BIOSCIENCES, INC. |
|
| May 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 ARCUS BIOSCIENCES, INC. |
|
| May 26, 2020 |
Exhibit 3.1 Amended and Restated Bylaws of Arcus Biosciences, Inc. GDSVF&H\ Table of Contents Page Article I Stockholders 1 1.1 Place of Meetings1 1.2 Annual Meeting1 1.3 Special Meetings1 1.4 Notice of Meetings1 1.5 Voting List2 1.6 Quorum2 1.7 Adjournments2 1.8 Voting and Proxies3 1.9 Action at Meeting3 1.10 Nomination of Directors3 1.11 Notice of Business at Annual Meetings7 1.12 Conduct of Mee |
|
| May 26, 2020 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 5, 2020 |
Arcus Biosciences Announces First Quarter 2020 Financial Results and Corporate Updates Exhibit 99.1 Arcus Biosciences Announces First Quarter 2020 Financial Results and Corporate Updates - Preliminary data from randomized trials involving three molecules in 4Q20 o AB928, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic o AB154, an anti-TIGIT antibody with the potential to be a new immuno-oncology backbone therapy o Zimberelimab, an anti-PD-1 antibody that |
|
| May 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 ARCUS BIOSCIENCES, INC. |
|
| May 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| April 21, 2020 |
RCUS / Arcus Biosciences, Inc. DEFA14A - - DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 21, 2020 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 7, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2020 ARCUS BIOSCIENCES, INC. |
|
| April 7, 2020 |
EXHIBIT 99.1 Arcus’s COVID-19 Statement Despite the ongoing situation with COVID-19, we continue to see relatively robust enrollment across our ongoing Arcus-sponsored studies at this time. Similar to other biotech and pharmaceutical companies, we believe this pandemic may ultimately cause delays in some of our clinical programs as well as delays initiating new studies and/or new clinical sites. H |
|
| March 5, 2020 |
Exhibit 99.1 Arcus Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates - Advanced three molecules into randomized Phase 2 trials to evaluate Arcus’s potential best-in-class therapies and highly differentiated therapeutic combinations; o Preliminary randomization data expected in 4Q20 for AB928 (the first and only dual A2a/A2b adenosine receptor antagonis |
|
| March 5, 2020 |
RCUS / Arcus Biosciences, Inc. / Jaen Juan C. - J. JAEN SC 13D 3.5.20 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Arcus Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969F109 (CUSIP Number) Juan Jaen, Ph.D. Arcus Biosciences, Inc. 3928 Point Eden Way Hayward, CA 94545 Telephone: (510) 694-6200 (Name, Address and Telephone Number of Person Authorize |
|
| March 5, 2020 |
Compensation Program for Non-Employee Directors. EXHIBIT 10.9 ARCUS BIOSCIENCES, INC. AMENDED COMPENSATION PROGRAM FOR NON-EMPLOYEE DIRECTORS EFFECTIVE AS OF MARCH 21, 2019 A. Cash Compensation: Annual cash retainers each paid quarterly, in arrears. 1. Retainer for each non-employee member of the Board: $35,000 2. Additional retainer for Lead Independent Director: $3,500 3. Additional retainer for Chair of Audit Committee: $15,000 4. Additional |
|
| March 5, 2020 |
Form of Stock Option Grant Notice (2020 Inducement Plan) EX-10.26 6 rcus-ex102682.htm EX-10.26 EXHIBIT 10.26 Arcus Biosciences, Inc. Stock Option Grant Notice (2020 Inducement Plan) Arcus Biosciences, Inc. (the “Company”), pursuant to its 2020 Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as se |
|
| March 5, 2020 |
Exhibit 4.2 ARCUS BIOSCIENCES, INC. DESCRIPTION OF COMMON STOCK Our authorized capital stock consists of 400,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share. A description of material terms and provisions of our certificate of incorporation and bylaws affecting the rights of holders of our common stock is set forth |
|
| March 5, 2020 |
RCUS / Arcus Biosciences, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on March 5, 2020 Registration No. |
|
| March 5, 2020 |
RCUS / Arcus Biosciences, Inc. / ROSEN TERRY J - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Arcus Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969F109 (CUSIP Number) Terry Rosen, Ph.D. Arcus Biosciences, Inc. 3928 Point Eden Way Hayward, CA 94545 Telephone: (510) 694-6200 (Name, Address and Telephone Number of Person Authori |
|
| March 5, 2020 |
EXHIBIT 10.24 December 4, 2019 VIA EMAIL Jennifer Jarrett RE:AMENDMENT TO SEPARATION AGREEMENT Dear Jennifer, This letter hereby amends the separation agreement dated January 3, 2019 (the “Separation Agreement”) between you and Arcus Biosciences, Inc. (the “Company”). Any capitalized terms used and not otherwise defined in this amendment shall have the meaning ascribed to them in the Separation Ag |
|
| March 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2020 ARCUS BIOSCIENCES, INC. |
|
| March 5, 2020 |
Arcus Biosciences, Inc. 2020 Inducement Plan EXHIBIT 10.25 Arcus Biosciences, Inc. 2020 Inducement Plan Adopted by the Board of Directors: January 22, 2020 1.General. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Rule 303A.08 of the NYSE Listed Company Manual Rules. A person who previously served as an Employee or Direc |
|
| March 5, 2020 |
EX-10.28 8 rcus-ex1028207.htm EX-10.28 EXHIBIT 10.28 [***] = CERTAIN INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT NO. 2 TO LICENSE AGREEMENT This AMENDMENT NO. 2 (the “Amendment”) is made and entered into as of the date of last signature, by and between Arcus Biosciences, Inc. (“Arcus”), with offices at 3928 Point E |
|
| March 5, 2020 |
Form of Restricted Stock Unit Grant Notice (2020 Inducement Plan) EXHIBIT 10.27 Arcus Biosciences, Inc. Restricted Stock Unit Grant Notice (2020 Inducement Plan) Arcus Biosciences, Inc. (the “Company”), pursuant to its 2020 Inducement Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is subject to all of the terms |
|
| March 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38419 Arcus Bioscienc |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Arcus Biosciences, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 03969F109 (CUSIP Number) |
|
| February 14, 2020 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2020 with respect to the common stock, par value $0.0001 per share of Arcus Biosciences, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Ru |
|
| February 13, 2020 |
RCUS / Arcus Biosciences, Inc. / Boxer Capital, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Arcus Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03969F109 (CUSIP Number) February 3, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 13, 2020 |
EX-99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G with respect to the common stock of Arcus Biosciences, Inc., par value $0.0001, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, and th |
|
| January 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Arcus Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969F109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| December 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2019 ARCUS BIOSCIENCES, INC. |
|
| November 25, 2019 |
8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A Amendment No. |
|
| November 5, 2019 |
Offer Letter, dated May 20, 2019, between the Company and Jason Barker Exhibit 10.1 May 20, 2019 Jason Barker [Address] Dear Jason: On behalf of Arcus Biosciences, Inc. (“Arcus” or the “Company”), I am pleased to invite you to join the Company in the role of VP, Finance, reporting initially to me in my capacity as Chief Operating and Financial Officer. Once you begin, your manager can provide you with additional information regarding your role and responsibilities. W |
|
| November 5, 2019 |
Separation Agreement, dated August 29, 2019, between the Company and Rekha Hemrajani Exhibit 10.2 August 29, 2019 Rekha Hemrajani [Address] Re:Separation Agreement Dear Rekha: This letter sets forth the terms of the separation agreement (the “Agreement”) that Arcus Biosciences, Inc. (the “Company”) is offering to you to aid in your employment transition. 1.Separation Date. Your last day of work with the Company and your employment termination date will be September 30, 2019 (the “ |
|
| November 5, 2019 |
RCUS / Arcus Biosciences, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38419 Arcus Biosciences, Inc. |
|
| November 5, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2019 ARCUS BIOSCIENCES, INC. |
|
| November 5, 2019 |
Arcus Biosciences Announces Third Quarter 2019 Financial Results and Recent Corporate Updates Exhibit 99.1 Arcus Biosciences Announces Third Quarter 2019 Financial Results and Recent Corporate Updates - Demonstrated best-in-class potential of AB928, a selective adenosine receptor antagonist that efficiently blocks both A2a and A2b receptors, as evidenced by a favorable safety profile when combined with multiple backbone therapies, and early signs of clinical activity in four Phase 1 dose-e |
